See the DrugPatentWatch profile for cosentyx
According to the sources provided, Cosentyx (secukinumab) is a medication used for the treatment of various conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. The recommended dosage modifications for Cosentyx can vary depending on the specific condition being treated and the patient's response to the medication.
For the treatment of moderate to severe plaque psoriasis, the recommended initial dosage of Cosentyx is 300 mg, administered by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by a maintenance dosage of 300 mg every 4 weeks. However, some patients may benefit from a higher dosage of 150 mg every week for the first 4 weeks, followed by 150 mg every 4 weeks [3].
For psoriatic arthritis, the recommended dosage of Cosentyx is 150 mg administered by subcutaneous injection every 4 weeks, after an initial loading dosage of 150 mg at weeks 0, 1, 2, 3, and 4 [3].
For ankylosing spondylitis, the recommended dosage of Cosentyx is 150 mg administered by subcutaneous injection every 4 weeks, after an initial loading dosage of 150 mg at weeks 0, 1, 2, 3, and 4 [3].
It is important to note that dosage modifications should be determined by a healthcare professional based on the individual patient's response to treatment and any potential side effects. Therefore, it is recommended to consult with a healthcare provider for specific dosage adjustments.
In summary, the recommended dosage modifications for Cosentyx vary depending on the condition being treated. For psoriasis, the initial dosage is 300 mg, followed by a maintenance dosage of 300 mg every 4 weeks. For psoriatic arthritis and ankylosing spondylitis, the recommended dosage is 150 mg every 4 weeks, following an initial loading dosage. It is important to consult with a healthcare professional for personalized dosage adjustments [3].
Sources:
[3] Cosentyx Product Information. Novartis Pharmaceuticals Corporation. Retrieved from
https://www.cosentyx.com/psoriatic-arthritis/treatment-dosing